Risvutatug Rezetecan Demonstrates Overall Survival Benefit Over Topotecan in Relapsed Small Cell Lung Cancer
Interim results from the pivotal Phase 3 ARTEMIS-008 trial (NCT06498479) show that risvutatug rezetecan, a B7-H3-directed antibody-drug conjugate, significantly reduced the risk of death...
Medicus Pharma Secures Worldwide Rights to Pfizer’s Discontinued CD228-Directed ADC in Deal Valued at...
Philadelphia-based Medicus Oncology gains global development and commercialization rights to PF-08046031 (CD228V), a melanotransferrin-targeted antibody-drug conjugate (ADC) originating from Pfizer's Seagen acquisition, as Pfizer retains a co-development role, milestone eligibility, and tiered royalties.
Sacituzumab Govitecan Plus Pembrolizumab Sustains Clinical Benefit Beyond First Progression in PD-L1–Positive Metastatic Triple-Negative...
Triple-negative breast cancer (TNBC) remains one of the most challenging and most malignant subtypes of breast cancer to treat. TNBC represents a heterogeneous group...
Seeing Where an Antibody Actually Goes: FluoSphera Licenses Debiopharm’s AbYlink™ to Pair Antibody Labeling...
Antibody-drug conjugates (ADCs) have a well-known failure mode that has nothing to do with target selection. A company can identify an antibody with excellent affinity for a validated tumor antigen, attach a potent cytotoxic payload to it, and still watch the resulting conjugate underperform in the clinic, not because the biology was wrong, but because the molecule never distributed through the tumor the way the binding assay predicted it would. A new agreement between two Swiss life-sciences companies, Debiopharm and FluoSphera, is aimed squarely at that gap, the space between knowing an antibody binds its target and knowing what it does once it is actually inside a tumor.
After CAR T-Cell Relapse in Mantle Cell Lymphoma, a CD79b-Targeted ADC Produces Durable Remission
A single-patient case report describes a prolonged remission with polatuzumab vedotin (Polivy®; Genentech/Roche) plus bendamustine (Treanda®; Teva/Cephalon) and rituximab (Rituxan®; Genentech/Biogen) in mantle cell lymphoma (MCL) after CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The regimen is approved for diffuse large B-cell lymphoma, not mantle cell lymphoma, and its use in this setting remains investigational.
Pipeline Watch: August 2026 – Dealmaking Accelerates, a Pivotal Lung Cancer Readout, and New...
August 2026 was a busy month for the antibody-drug conjugate (ADC) field, with activity spanning the full arc of development. Highlights included early discovery partnerships, manufacturing alliances, a practice-changing phase 3 readout in lung cancer, and the first dosing of a novel Treg-depleting ADC.
B7-H3 Antibody-Drug Conjugates Gain Momentum as Frontline Standards Shift Across Solid Tumors
B7-H3 Antibody-Drug Conjugates Gain Momentum as Frontline Standards Shift Across Solid Tumors
Lonza Expands ADC Capabilities with Strategic Investments and Integrated Technologies
Lonza Expands ADC Capabilities with Strategic Investments and Integrated Technologies
Novartis and Myricx Bio: Pioneering Next-Generation ADC Innovation with N-Myristoyltransferase Inhibitor Payloads
Novartis and Myricx Bio: Pioneering Next-Generation ADC Innovation with N-Myristoyltransferase Inhibitor Payloads
Practice-Changing Advances in Early HER2-Positive Breast Cancer: ASCO 2026 and FDA Approvals Establish Trastuzumab...
Practice-Changing Advances in Early HER2-Positive Breast Cancer: ASCO 2026 and FDA Approvals Establish Trastuzumab Deruxtecan as a New Standard
